Skip to content
Shameless Cloning

Search Shameless Cloning

Search superinvestors, stocks, insiders and members of Congress

Avoro Capital Advisors LLC · Q2 2026 13F · SEC CIK 1633313

Behzad Aghazadeh portfolio

Hedge fundAvoro Capital Advisors 13F holdings. Filed 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value
$11.1B
Reported positions
26
Top holdings a year, 3 yrs
+22.0%
Assets under management
$13.6B

Behzad Aghazadeh is the founder of Avoro Capital Advisors, which reported 26 positions worth $11.1B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were United Therapeutics Corp Del (UTHR, 13.5%), Ascendis Pharma A/s (ASND, 12.2%), Krystal Biotech Inc (KRYS, 9.6%). A portfolio copying its top holdings returned 22.0% a year over the last 3 years, against 22.3% for the S&P 500.

Behzad Aghazadeh holdings all 26 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Behzad Aghazadeh 13F holdings
Stock% of 13F valueShare changeReported value
UTHRUnited Therapeutics Corp Del13.5%+5.6%$1.5B
ASNDAscendis Pharma A/s12.2%—$1.4B
KRYSKrystal Biotech Inc9.6%+0.0%$1.1B
MDGLMadrigal Pharmaceuticals Inc8.8%+0.8%$984.4M
ARGNFArgenx SE8.3%+0.0%$927.8M
ARWRArrowhead Pharmaceuticals in8.3%+6.1%$925.6M
KYMRKymera Therapeutics Inc7.7%+0.0%$857.1M
RVMDRevolution Medicines Inc3.9%-2.0%$430.2M
CYTKCytokinetics3.8%+50.0%$425.9M
CELCCelcuity Inc3.2%+0.7%$355.7M
GPCRStructure Therapeutics F Unspo3.2%+0.0%$351.8M
XENEXenon Pharmaceuticals Inc3.1%+0.0%$348.7M
24477V105Definium Therapeutics Inc3.0%+43.8%$338.2M
QUREUniqure NV2.8%+12.9%$309.9M
VERAVera Therapeutics Inc Class A2.2%-2.8%$245.6M
TSHATaysha Gene Therapies Inc1.5%+10.1%$162.7M
OCULOcular Therapeutix Inc1.1%+1.8%$123.1M
GLTODamora Therapeutics Inc0.9%+0.0%$98.4M
COAGHemab Therapeutics Holdings Inc0.6%—$70.7M
GHRSGh Research PLC0.4%+0.0%$48.4M
VRDNViridian Therapeutics Inc0.4%+66.7%$45.9M
SEPNSepterna Inc0.4%+0.0%$44.8M
AVTXAvalo Therapeutics Inc0.4%+65.5%$43.1M
FTHFaeth Therapeutics Inc0.3%—$36.1M
AADIWhitehawk Therapeutics Inc0.1%+0.0%$13.1M
LXEOLexeo Therapeutics Inc0.1%-20.6%$6.9M

What Behzad Aghazadeh bought and sold in Q2 2026, against Q1 2026.

New positions

Added to

Reduced

Sold out

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year
+27.4% /yr
S&P 500 +11.7%
3 years
+22.0% /yr
S&P 500 +22.3%
5 years
+14.1% /yr
S&P 500 +10.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter13F valuePositions
Q2 2026$11.1B26
Q1 2026$10.2B30
Q4 2025$10.2B33
Q3 2025$7.7B30
Q2 2025$5.7B30
Q1 2025$6.4B33
Q4 2024$7.1B39
Q3 2024$6.9B35
Q2 2024$7.5B41
Q1 2024$8.6B46
Q4 2023$7.2B42
Q3 2023$6.4B45

Questions about Behzad Aghazadeh's portfolio

Who is Behzad Aghazadeh?

Behzad Aghazadeh is the founder of Avoro Capital Advisors, a hedge fund that files its US stock holdings with the SEC on Form 13F under the name Avoro Capital Advisors LLC.

What stocks does Behzad Aghazadeh own?

Avoro Capital Advisors LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 26 positions worth $11.1B. The largest are United Therapeutics Corp Del (UTHR) at 13.5%, Ascendis Pharma A/s (ASND) at 12.2%, Krystal Biotech Inc (KRYS) at 9.6%, Madrigal Pharmaceuticals Inc (MDGL) at 8.8% and Argenx SE (ARGNF) at 8.3%.

What did Behzad Aghazadeh buy last quarter?

In Q2 2026, Avoro Capital Advisors LLC added a new position in Ascendis Pharma A/s (ASND), a new position in Hemab Therapeutics Holdings Inc (COAG), a new position in Faeth Therapeutics Inc (FTH), Viridian Therapeutics Inc (VRDN) (+66.7% shares), Avalo Therapeutics Inc (AVTX) (+65.5% shares) and Cytokinetics (CYTK) (+50.0% shares), compared with its Q1 2026 filing.

What did Behzad Aghazadeh sell last quarter?

In Q2 2026, Avoro Capital Advisors LLC sold all of Ascendis Pharma A/s, sold all of Apellis Pharmaceuticals Inc (APLS), sold all of Centessa Pharmaceuticals PLC (CNTA), sold all of Terns Pharmaceuticals Inc (TERN), sold all of Soleno Therapeutics Inc (SLNO) and Lexeo Therapeutics Inc (LXEO) (-20.6% shares), compared with its Q1 2026 filing.

How has Behzad Aghazadeh's portfolio performed?

A portfolio copying Avoro Capital Advisors LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +22.0% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: +27.4% against +11.7%. Over 5 years: +14.1% a year against +10.6%.

When is Avoro Capital Advisors LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Avoro Capital Advisors LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Avoro Capital Advisors LLC manage?

Avoro Capital Advisors LLC reported $13.6B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $11.1B.

Embed, cite or share this

Free to use with a link back. The data updates every filing day, and so does the embedded chart.

Embed this chart
Citation
Link